Keyword: Lonza


Wolfgang Wienand to Join Lonza as New CEO

02.04.2024 -

Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional...


Lonza Buys Biologics Plant From Roche for $1.2 Billion

21.03.2024 -

Lonza has signed an agreement to acquire Genentech's biologics manufacturing site in Vacaville, California (USA) from Roche. The Swiss pharmaceutical company announced...


Large-Scale Production Announced by Epsilogen and Lonza for Ovarian Cancer Treatment

05.03.2024 -

Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out...


Lonza and Oxford Nanopore to Collaborate on mRNA Analysis

30.01.2024 -

Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation...


Lonza Announces New Mid-Term Guidance 2024 – 2028

17.10.2023 -

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Chemistry & Life Sciences

Spray Drying for Inhalation: the Challenges of Scale-up

16.10.2023 -

When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key...


Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

06.10.2023 -

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...

Research / Laboratory

Successful Clinical to Commercial Bioconjugate Manufacturing

Lonza AG -

Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.